Find Abaloparatide Acetate manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

VMF

NDC API

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

Health Canada Patents

DIGITAL CONTENT

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

GLOBAL SALES INFORMATION

Annual Reports

NA

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: Tymlos, Ba058, Unii-avk0i6hy2u, Bim-44058, Abaloparatide [usan:inn], Abaloparatide-sc
Molecular Formula
C174H300N56O49
Molecular Weight
3961  g/mol
InChI Key
BVISQZFBLRSESR-XSCWXTNMSA-N

Abaloparatide Acetate
Abaloparatide is a 34 amino acid synthetic analog of human parathyroid hormone-related protein (PTHrP) (PTHrP(1-34) analog), with bone-growing and bone density conserving activities. Upon subcutaneous administration, abaloparatide acts similar to PTHrP and targets, binds to and activates parathyroid hormone 1 (PTH1) receptor (PTH1R), a G protein-coupled receptor (GPCR) expressed in osteoblasts and bone stromal cells. PTH1R activates the cyclic AMP (cAMP) signaling pathway and the bone anabolic signaling pathway, leading to bone growth, increased bone mineral density (BMD) and volume. This correlates with increased bone mass and strength and prevents or treats osteoporosis and decreases fractures.
1 2D Structure

Abaloparatide Acetate

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
(4S)-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-aminopropanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-4-carboxybutanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-5-oxopentanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-carboxypropanoyl]amino]hexanoyl]amino]acetyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]-5-oxopentanoyl]amino]-3-carboxypropanoyl]amino]-4-methylpentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-amino-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-2-methyl-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-oxopentanoic acid
2.1.2 InChI
InChI=1S/C174H300N56O49/c1-26-93(20)136(228-165(274)126(80-232)224-141(250)101(39-28-32-56-176)200-129(236)78-195-140(249)100(38-27-31-55-175)201-161(270)123(73-133(243)244)223-160(269)121(71-98-76-190-82-197-98)220-158(267)118(68-90(14)15)216-155(264)114(64-86(6)7)213-148(257)107(45-50-127(180)234)207-159(268)120(70-97-75-189-81-196-97)219-151(260)111(49-54-132(241)242)209-164(273)125(79-231)225-167(276)135(92(18)19)227-139(248)94(21)179)168(277)210-108(46-51-128(181)235)149(258)222-124(74-134(245)246)162(271)217-112(62-84(2)3)152(261)205-105(44-37-61-194-173(187)188)143(252)203-103(42-35-59-192-171(183)184)142(251)204-104(43-36-60-193-172(185)186)144(253)206-110(48-53-131(239)240)150(259)214-115(65-87(8)9)154(263)215-113(63-85(4)5)153(262)208-109(47-52-130(237)238)147(256)202-102(40-29-33-57-177)145(254)211-116(66-88(10)11)156(265)218-119(69-91(16)17)166(275)230-174(24,25)170(279)226-106(41-30-34-58-178)146(255)212-117(67-89(12)13)157(266)221-122(72-99-77-191-83-198-99)163(272)229-137(96(23)233)169(278)199-95(22)138(182)247/h75-77,81-96,100-126,135-137,231-233H,26-74,78-80,175-179H2,1-25H3,(H2,180,234)(H2,181,235)(H2,182,247)(H,189,196)(H,190,197)(H,191,198)(H,195,249)(H,199,278)(H,200,236)(H,201,270)(H,202,256)(H,203,252)(H,204,251)(H,205,261)(H,206,253)(H,207,268)(H,208,262)(H,209,273)(H,210,277)(H,211,254)(H,212,255)(H,213,257)(H,214,259)(H,215,263)(H,216,264)(H,217,271)(H,218,265)(H,219,260)(H,220,267)(H,221,266)(H,222,258)(H,223,269)(H,224,250)(H,225,276)(H,226,279)(H,227,248)(H,228,274)(H,229,272)(H,230,275)(H,237,238)(H,239,240)(H,241,242)(H,243,244)(H,245,246)(H4,183,184,192)(H4,185,186,193)(H4,187,188,194)/t93-,94-,95-,96+,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,135-,136-,137-/m0/s1
2.1.3 InChI Key
BVISQZFBLRSESR-XSCWXTNMSA-N
2.1.4 Canonical SMILES
CCC(C)C(C(=O)NC(CCC(=O)N)C(=O)NC(CC(=O)O)C(=O)NC(CC(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCC(=O)O)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(C)(C)C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CC1=CN=CN1)C(=O)NC(C(C)O)C(=O)NC(C)C(=O)N)NC(=O)C(CO)NC(=O)C(CCCCN)NC(=O)CNC(=O)C(CCCCN)NC(=O)C(CC(=O)O)NC(=O)C(CC2=CN=CN2)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCC(=O)N)NC(=O)C(CC3=CN=CN3)NC(=O)C(CCC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(C)N
2.1.5 Isomeric SMILES
CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NC(C)(C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC3=CN=CN3)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)N
2.2 Synonyms
2.2.1 MeSH Synonyms

1. Ba058

2. Tymlos

2.2.2 Depositor-Supplied Synonyms

1. Tymlos

2. Ba058

3. Unii-avk0i6hy2u

4. Bim-44058

5. Abaloparatide [usan:inn]

6. Abaloparatide-sc

7. Avk0i6hy2u

8. Chembl4084894

9. Bdbm50246337

10. C2.29-methyl(22-l-glutamic Acid(f>e),23-l-leucine(f>l),25-l-glutamic Acid(h>e),26-l-lysine(h>k),28-l-leucine(i>l),30-l-lysine(e>k),31-l-leucine(i>l))human Parathyroid Hormone-related Protein-(1-34)-proteinamide

2.3 Create Date
2014-08-23
3 Chemical and Physical Properties
Molecular Weight 3961 g/mol
Molecular Formula C174H300N56O49
XLogP3-20.9
Hydrogen Bond Donor Count61
Hydrogen Bond Acceptor Count60
Rotatable Bond Count145
Exact Mass3959.2738250 g/mol
Monoisotopic Mass3958.2704702 g/mol
Topological Polar Surface Area1740 Ų
Heavy Atom Count279
Formal Charge0
Complexity9310
Isotope Atom Count0
Defined Atom Stereocenter Count34
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Pharmacology and Biochemistry
4.1 MeSH Pharmacological Classification

Bone Density Conservation Agents

Agents that inhibit BONE RESORPTION and/or favor BONE MINERALIZATION and BONE REGENERATION. They are used to heal BONE FRACTURES and to treat METABOLIC BONE DISEASES such as OSTEOPOROSIS. (See all compounds classified as Bone Density Conservation Agents.)


USDMF

read-more
read-more

01

Medlab Asia & Asia Health
Not Confirmed

01

Medlab Asia & Asia Health
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2024-01-08

Pay. Date : 2023-12-08

DMF Number : 39223

Submission : 2023-11-30

Status : Active

Type : II

blank

02

Medlab Asia & Asia Health
Not Confirmed

02

Medlab Asia & Asia Health
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2022-05-16

Pay. Date : 2022-05-06

DMF Number : 34697

Submission : 2020-05-30

Status : Active

Type : II

blank

03

Medlab Asia & Asia Health
Not Confirmed

03

Medlab Asia & Asia Health
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 36475

Submission : 2021-12-03

Status : Active

Type : II

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Drugs in Development

read-more
read-more

Details:

Theramex will commercialise and distribute Eladynos (abaloparatide), a novel bone forming agent indicated for the treatment of osteoporosis in postmenopausal women at increased risk of fractures on an exclusive basis in the European Economic Area, UK , Australia and Brazil.


Lead Product(s): Abaloparatide Acetate

Therapeutic Area: Musculoskeletal Brand Name: Eladynos

Study Phase: ApprovedProduct Type: Peptide

Sponsor: Theramex

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement March 20, 2023

blank

01

CPHI Middle east
Not Confirmed
CPHI Middle east
Not Confirmed

Details : Theramex will commercialise and distribute Eladynos (abaloparatide), a novel bone forming agent indicated for the treatment of osteoporosis in postmenopausal women at increased risk of fractures on an exclusive basis in the European Economic Area, UK , A...

Brand Name : Eladynos

Molecule Type : Peptide

Upfront Cash : Undisclosed

March 20, 2023

blank

Details:

Radius’ lead product, TYMLOS® (abaloparatide) was launched in the U.S. in 2017 for the treatment of postmenopausal women with osteoporosis at high risk for fracture.


Lead Product(s): Abaloparatide Acetate

Therapeutic Area: Musculoskeletal Brand Name: Tymlos

Study Phase: ApprovedProduct Type: Peptide

Sponsor: Gurnet Point Capital

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Acquisition August 15, 2022

blank

02

CPHI Middle east
Not Confirmed
CPHI Middle east
Not Confirmed

Details : Radius’ lead product, TYMLOS® (abaloparatide) was launched in the U.S. in 2017 for the treatment of postmenopausal women with osteoporosis at high risk for fracture.

Brand Name : Tymlos

Molecule Type : Peptide

Upfront Cash : Undisclosed

August 15, 2022

blank

Details:

The acquisition of Radius by Gurnet Point and Patient Square provides our shareholders with attractive, immediate value at a compelling premium, in addition to the potential future upside of TYMLOS (abaloparatide) through the CVR.


Lead Product(s): Abaloparatide Acetate

Therapeutic Area: Musculoskeletal Brand Name: Tymlos

Study Phase: ApprovedProduct Type: Peptide

Sponsor: Gurnet Point Capital

Deal Size: $890.0 million Upfront Cash: $547.0 million

Deal Type: Acquisition August 15, 2022

blank

03

CPHI Middle east
Not Confirmed
CPHI Middle east
Not Confirmed

Details : The acquisition of Radius by Gurnet Point and Patient Square provides our shareholders with attractive, immediate value at a compelling premium, in addition to the potential future upside of TYMLOS (abaloparatide) through the CVR.

Brand Name : Tymlos

Molecule Type : Peptide

Upfront Cash : $547.0 million

August 15, 2022

blank

Details:

The acquisition of Radius by Gurnet Point and Patient Square provides our shareholders with attractive, immediate value at a compelling premium, in addition to the potential future upside of TYMLOS (abaloparatide) through the CVR.


Lead Product(s): Abaloparatide Acetate

Therapeutic Area: Musculoskeletal Brand Name: Tymlos

Study Phase: ApprovedProduct Type: Peptide

Sponsor: Gurnet Point Capital

Deal Size: $890.0 million Upfront Cash: $547.0 million

Deal Type: Acquisition June 23, 2022

blank

04

CPHI Middle east
Not Confirmed
CPHI Middle east
Not Confirmed

Details : The acquisition of Radius by Gurnet Point and Patient Square provides our shareholders with attractive, immediate value at a compelling premium, in addition to the potential future upside of TYMLOS (abaloparatide) through the CVR.

Brand Name : Tymlos

Molecule Type : Peptide

Upfront Cash : $547.0 million

June 23, 2022

blank

Details:

The data for spine BMD vs. baseline showed abalo-TDS had a 7.1% increase vs. TYMLOS (abaloparatide) +10.9%, both considered clinically meaningful. Despite missing the non-inferiority margin, the transdermal system demonstrated a bone building benefit to patients.


Lead Product(s): Abaloparatide Acetate

Therapeutic Area: Musculoskeletal Brand Name: Tymlos

Study Phase: Phase IIIProduct Type: Peptide

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 01, 2022

blank

05

CPHI Middle east
Not Confirmed
CPHI Middle east
Not Confirmed

Details : The data for spine BMD vs. baseline showed abalo-TDS had a 7.1% increase vs. TYMLOS (abaloparatide) +10.9%, both considered clinically meaningful. Despite missing the non-inferiority margin, the transdermal system demonstrated a bone building benefit to ...

Brand Name : Tymlos

Molecule Type : Peptide

Upfront Cash : Not Applicable

June 01, 2022

blank

Details:

Company announced phase 3 topline results from the wearABLe study did not meet its primary endpoint evaluating the NI of BA058 (abaloparatide) in postmenopausal women with osteoporosis.


Lead Product(s): Abaloparatide Acetate

Therapeutic Area: Musculoskeletal Brand Name: BA058

Study Phase: Phase IIIProduct Type: Peptide

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable December 08, 2021

blank

06

CPHI Middle east
Not Confirmed
CPHI Middle east
Not Confirmed

Details : Company announced phase 3 topline results from the wearABLe study did not meet its primary endpoint evaluating the NI of BA058 (abaloparatide) in postmenopausal women with osteoporosis.

Brand Name : BA058

Molecule Type : Peptide

Upfront Cash : Not Applicable

December 08, 2021

blank

Details:

Endo obtained the rights to abaloparatide-subcutaneous injection and abaloparatide-transdermal patch, a novel formulation and route of administration currently undergoing clinical development. Endo, will be responsible for all commercial activities related to abaloparatide.


Lead Product(s): Abaloparatide Acetate

Therapeutic Area: Musculoskeletal Brand Name: BA058

Study Phase: Phase IIIProduct Type: Peptide

Sponsor: Endo International

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement January 05, 2021

blank

07

PALADIN LABS

Canada
arrow
CPHI Middle east
Not Confirmed

PALADIN LABS

Canada
arrow
CPHI Middle east
Not Confirmed

Details : Endo obtained the rights to abaloparatide-subcutaneous injection and abaloparatide-transdermal patch, a novel formulation and route of administration currently undergoing clinical development. Endo, will be responsible for all commercial activities relat...

Brand Name : BA058

Molecule Type : Peptide

Upfront Cash : Undisclosed

January 05, 2021

blank

Details:

The study was designed to look at the effects on bone mineral density of abaloparatide delivered via a novel transdermal device (“abaloparatide-patch”) compared with the current subcutaneous formulation, marketed as TYMLOS®.


Lead Product(s): Abaloparatide Acetate

Therapeutic Area: Musculoskeletal Brand Name: BA058

Study Phase: Phase IIIProduct Type: Peptide

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 08, 2020

blank

08

CPHI Middle east
Not Confirmed
CPHI Middle east
Not Confirmed

Details : The study was designed to look at the effects on bone mineral density of abaloparatide delivered via a novel transdermal device (“abaloparatide-patch”) compared with the current subcutaneous formulation, marketed as TYMLOS®.

Brand Name : BA058

Molecule Type : Peptide

Upfront Cash : Not Applicable

September 08, 2020

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

US Medicaid Prescriptions

read-more
read-more

01

arrow
CPHI Middle east
Not Confirmed
arrow
CPHI Middle east
Not Confirmed

Company :

Abaloparatide

Drug Cost (USD) : 156,712,784

Year : 2022

Prescribers : 11168

Prescriptions : 60207

blank

02

arrow
CPHI Middle east
Not Confirmed
arrow
CPHI Middle east
Not Confirmed

Company :

Abaloparatide

Drug Cost (USD) : 137,835,466

Year : 2021

Prescribers : 11638

Prescriptions : 58817

blank

03

arrow
CPHI Middle east
Not Confirmed
arrow
CPHI Middle east
Not Confirmed

Company :

Abaloparatide

Drug Cost (USD) : 109,841,019

Year : 2019

Prescribers : 11125

Prescriptions : 53463

blank

04

arrow
CPHI Middle east
Not Confirmed
arrow
CPHI Middle east
Not Confirmed

Company :

Abaloparatide

Drug Cost (USD) : 52,079,801

Year : 2018

Prescribers : 6480

Prescriptions : 26090

blank

05

arrow
CPHI Middle east
Not Confirmed
arrow
CPHI Middle east
Not Confirmed

Company :

Abaloparatide

Drug Cost (USD) : 4,903,353

Year : 2017

Prescribers : 1184

Prescriptions : 2457

blank

06

arrow
CPHI Middle east
Not Confirmed
arrow
CPHI Middle east
Not Confirmed

Company :

Abaloparatide

Drug Cost (USD) : 0

Year : 2016

Prescribers :

Prescriptions : 0

blank

07

arrow
CPHI Middle east
Not Confirmed
arrow
CPHI Middle east
Not Confirmed

Company :

Abaloparatide

Drug Cost (USD) : 0

Year : 2015

Prescribers :

Prescriptions : 0

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty